Eli Lilly and Company

The Upjohn Co.

David N Brems

Diane L Bakaysa

Bruce H Frank

Henry Acken Havel

Allen H Pekar

Sherwood Russ Lehrman

Scott M Plaisted

Jody L Tuls

Henry A Havel

The present invention provides analogs of animal somatotropins particularly with changes in the amino acids between residue 96 to 133 which are changed to reduce hydrophobicity or helical stability.

Somatotropin analogs

Analogs of human insulin containing an aspartic acid at position 1 of the B chain (Asp.sup.B1), and optionally, having a gln modification at position 13 (Gln.sup.B13), display modified physico-chemical and pharmacokinetic properties which enable them to be long acting. These analogs are useful in the treatment of hyperglycemia because they are soluble and display an increased tendency to self-associate.

Asp.sup.B1 insulin analogs

The present invention discloses a human insulin analog hexamer complex and formulations. More specifically, the present invention relates to various parenteral formulations, which comprise: human insulin analogs in a hexamer conformation, zinc ions, and at least three molecules of a phenolic derivative selected from the group consisting of m-cresol, phenol, or a mixture of m-cresol and phenol. The formulation provides a rapid onset of action.

Insulin analog formulations

Growing community of inventors

Indianapolis, IN, United States of America

David N Brems